Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
Longeveron NASDAQ:LGVN on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.Shares of the company, which have gained 32% so far this year, plunged nearly 60% in after-hours t…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.